Key points from article :
25 ml/kg intravenous NuPlasma yFFP positively affected assessments for Parkinson patients.
Backed by 3-month data, 19 patients --9 were administered yFFP; 10 given placebo.
yFFP recipients achieved improvements in 30 out of 43 assessment categories.
NuPlasma yFFP outperforms the placebo in every assessment subset.
Method has shown early success in some clinical trials of neurodegenerative diseases.
Higher standards, increased testing, hold period, age and gender segmentation to be employed.
Research by The Neurology Center.
